Emerging BioTalk
  • Home
  • About Us
  • Contact
  • Search
  • Menu

CDMO: Afraid of tech transfer? There’s no need!

May 6, 2021/in Uncategorized /by Heike Monange

Tech transfer appears on the agenda of almost every biotech company. After identifying a suitable molecule, biotechs need support from external partners on the way to commercialization. However, many fear that tech transfer could slow them down or that they may be locked in with royalty fees. Working with the right partner can make all the difference.

Tech transfers come in many flavors. They may be performed at an early stage, when a biotech is ready to enter pre-clinical phase for a novel therapeutic candidate. Or, they may happen at a later stage when production and analysis procedures have already been established and clinical data are available. We interviewed experts from the

MilliporeSigma
Merck
BioReliance® End-to-End Solutions team to demystify tech transfer and to share some best practices.

“Many biotechs do not have a long-term strategy, and that’s fine with us. After IND filing, some prefer to continue the development with a contract manufacturing and development organization (CDMO), others choose to either outlicense or sell their molecule to a pharma company,” Karima Medini, Senior Analytical Expert BioReliance® End-to-End Solutions at

MilliporeSigma
Merck
, said.

“Our clients can take their project from milestone to milestone and remain flexible in their decisions. We do not lock them in with royalty fees but support them to quickly and flawlessly transfer their processes to the receiving pharma company, or take it to market on their own once they are ready.”

Tech transfer to CDMO

In a typical early-stage project, a biotech company has identified a therapeutic molecule and seeks support from an external partner to set up the production processes and analytical methods needed to achieve investigational new drug (IND) filing.

For many startup companies, this is the first time they are ever involved in a tech transfer, so working with a CDMO partner that offers long-standing expertise can make all the difference.

“Over the years, we have established an optimized process that helps us understand where biotechs are on their journey and find out how we can best support them,” said Laetitia Botrel, Head of Business Planning and Operation, BioReliance® End-to-End Solutions,

MilliporeSigma
Merck
. “Once we have identified the gaps and evaluated the risks associated with a project, we can advise our clients on how to move forward.”

What are the key success factors for a robust program that facilitates and accelerates tech transfer at any stage? Learn more about the combination of:

  • Multidisciplinary expert teams
  • Standardized information transfer
  • Single-use technologies
  • Analytical panels

Read the full article published on Labiotech.eu and reach out to us!

https://www.labiotech.eu/partner/demystifying-tech-transfer-cdmo/

  • Author
  • Recent Posts
Heike Monange
Global Marketing Communications at MilliporeSigma
The team that delivers BioReliance® End-to-End Solutions has the expertise and flexibility to support accelerated development and commercialization of biologics.With experience developing more than 250 biologics, the team can tailor analytical packages with validated quality attributes and flexibility to support companies in the development of molecules at all stages.

The analytical development and optimization team works closely with our process development and manufacturing teams to reduce uncertainty and mitigate risk at the very early stage of development so that to ensure the success.The strength of our analytical team lies in an open mindset and expertise to tailor programs fitting needs of the company and the pipeline asset.
Latest posts by Heike Monange (see all)
  • CDMO: Afraid of tech transfer? There’s no need! - May 6, 2021
  • A Streamlined Approach to Analytical Method Development and Implementation - October 8, 2020

+3
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share by Mail
http://emergingbiotalk.com/wp-content/uploads/2021/05/Featured-Image.jpg 953 1429 Heike Monange http://emergingbiotalk.com/wp-content/uploads/2020/05/emergingbiotalk-header.png Heike Monange2021-05-06 07:26:072022-10-19 08:50:28CDMO: Afraid of tech transfer? There's no need!

Biotech Resource Hub >>

  • SUBSCRIBE TO OUR BLOG
  • SUBMIT YOUR BLOG POST

Latest News

  • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
  • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
  • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

Categories

  • Bioprocessing
  • Biosafety Testing
  • End-to-End Solutions
  • Frontpage Article
  • Gene Therapy
  • Investigator's Brochure
  • News
  • Uncategorized
  • Vaccines
  • Viral Vectors
  • Webinar

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • April 2020
  • SUBSCRIBE TO OUR BLOG
  • SUBMIT YOUR BLOG POST

Latest News

  • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
  • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
  • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

Categories

  • Bioprocessing
  • Biosafety Testing
  • End-to-End Solutions
  • Frontpage Article
  • Gene Therapy
  • Investigator's Brochure
  • News
  • Uncategorized
  • Vaccines
  • Viral Vectors
  • Webinar

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • April 2020

Tags

applications bioprocessing biotech blazar Congratulations Content education Europe FDA Format gene therapy grant grants Investigator's Brochure molecule new NGS Pharmaceuticals program services symposia tags things Tone VAR2 viral assurance viral clearance virus virus detection winner

Business Hours

Our support Hotline is available 24 Hours a day: (555) 343 456 7891

  • Monday-Friday: 9am to 5pm
  • Saturday: 10am to 2pm
  • Sunday: Closed

Latest News

  • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
  • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
  • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am
  • The Future of BiopharmaDecember 6, 2022 - 4:39 am
  • Last chance: 3rd Annual Startup Symposium – Day 3November 10, 2022 - 5:39 am
  • The Lack of Funding for Women Entrepreneurs Doesn’t Stop Them from Launching – But We Still Have a Long Way to Go – And We Can Help Each Other. Assurea is ROOTING FOR YOU!October 21, 2022 - 8:27 am

Categories

  • Bioprocessing
  • Biosafety Testing
  • End-to-End Solutions
  • Frontpage Article
  • Gene Therapy
  • Investigator's Brochure
  • News
  • Uncategorized
  • Vaccines
  • Viral Vectors
  • Webinar
  • Author
  • Recent Posts
Heike Monange
Global Marketing Communications at MilliporeSigma
The team that delivers BioReliance® End-to-End Solutions has the expertise and flexibility to support accelerated development and commercialization of biologics.With experience developing more than 250 biologics, the team can tailor analytical packages with validated quality attributes and flexibility to support companies in the development of molecules at all stages.

The analytical development and optimization team works closely with our process development and manufacturing teams to reduce uncertainty and mitigate risk at the very early stage of development so that to ensure the success.The strength of our analytical team lies in an open mindset and expertise to tailor programs fitting needs of the company and the pipeline asset.
Latest posts by Heike Monange (see all)
  • CDMO: Afraid of tech transfer? There’s no need! - May 6, 2021
  • A Streamlined Approach to Analytical Method Development and Implementation - October 8, 2020
+3
© 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. | Privacy Policy | Cookie Settings
The Art of Gene Therapy Digital Summit: EMEA 2021 From University Start-up to Clinical Stage Biotech
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. We use cookies in our website to give you the most relevant experience. By clicking or navigating the site, you are accepting the use of all our cookies according to our Cookie Policy / Privacy Statement. You are free to decide in the Cookie Settings which categories you would like to allow. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy

Accept All CookiesCookie Settings

Cookie and Privacy Settings



Cookie Preferences

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about how we use and share your data, please follow this link.
Privacy Statement

Necessary

Always Active
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

Functional

These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., pop-up notification choices).Changes will take effect once you reload the page.

Targeting

These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.

Confirm My ChoicesAllow AllDisable All

loading

Please wait while you are redirected to the right page...

Please share your location to continue.

Check our help guide for more info.

share your location